We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · May 02, 2022

Effectiveness of Eribulin as First-Line or Second-Line Chemotherapy for HER2-Negative Hormone-Resistant Advanced or MBC

Breast Cancer (Tokyo, Japan)

 

Additional Info

Breast Cancer (Tokyo, Japan)
Effectiveness of eribulin as first-line or second-line chemotherapy for HER2-negative hormone-resistant advanced or metastatic breast cancer: findings from the multi-institutional, prospective, observational KBCRN A001: E-SPEC study
Breast Cancer 2022 Apr 23;[EPub Ahead of Print], Y Kikawa, T Kotake, S Tsuyuki, Y Kang, S Takahara, Y Fujimoto, H Yamashiro, H Yoshibayashi, M Takada, R Yasuoka, K Nakatsukasa, K Yamagami, H Suwa, T Okuno, I Nakayama, T Kato, N Ogura, Y Moriguchi, H Ishiguro, T Kagimura, T Taguchi, T Sugie, M Toi

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading